Lifecore Biomedical Announces Commercial Launch of Corgel™ Biohydrogel

Hyaluronan Based Research Hydrogel

CHASKA, MN. – May 11, 2009 – LIFECORE BIOMEDICAL, LLC announced today the commercial launch of its proprietary Corgel™ BioHydrogel research kits. Corgel is a hyaluronan (hyaluronic acid) based biocompatible hydrogel. It was initially conceived and developed by scientists at Cleveland Clinic as a tissue bulking agent and drug delivery matrix. The tunability of the matrix and the biocompatibility also allows for the direct inclusion of cells or bioactive agents.

Lifecore procured an exclusive license agreement with Cleveland Clinic in 2007 and has been actively developing the technology by completing ISO 10993 Safety and Toxicity studies, as well as exploring modifications and variables to the technology. Lifecore now looks forward to collaborative development for use in surgical and transcatheter applications in vascular surgery, cardiology, ophthalmology, orthopedics, aesthetics, ENT, drug delivery, tissue engineering and regenerative medicine and several other medical fields.

For more information on Corgel™ BioHydrogel please contact Lifecore Biomedical at 952-368-6321 or by email at corgel@lifecore.com

About Lifecore Biomedical

Lifecore Biomedical, LLC is a portfolio company of Warburg Pincus and has been in business over 40 years. It develops, manufactures, and markets hyaluronan based biomaterials and aseptically fills syringes and vials as medical devices and drugs for use in various human and veterinary markets.
News and general information are available through the Company’s website at www.lifecore.com or by telephone at 952-368-4300.

CONTACT: 952-368-4300
Kipling Thacker, Ph.D., Vice President of New Business Development
Larry Hiebert, Vice President and General Manager